Titre : Lame limitante postérieure

Lame limitante postérieure : Questions médicales fréquentes

Termes MeSH sélectionnés :

Probability
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Lame limitante postérieure : Questions médicales les plus fréquentes", "headline": "Lame limitante postérieure : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Lame limitante postérieure : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-30", "dateModified": "2025-04-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Lame limitante postérieure" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Membrane basale", "url": "https://questionsmedicales.fr/mesh/D001485", "about": { "@type": "MedicalCondition", "name": "Membrane basale", "code": { "@type": "MedicalCode", "code": "D001485", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A10.615.179" } } }, "about": { "@type": "MedicalCondition", "name": "Lame limitante postérieure", "alternateName": "Descemet Membrane", "code": { "@type": "MedicalCode", "code": "D003886", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Steven E Wilson", "url": "https://questionsmedicales.fr/author/Steven%20E%20Wilson", "affiliation": { "@type": "Organization", "name": "Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: wilsons4@ccf.org." } }, { "@type": "Person", "name": "Takahiko Hayashi", "url": "https://questionsmedicales.fr/author/Takahiko%20Hayashi", "affiliation": { "@type": "Organization", "name": "Department of Ophthalmology, Nihon University of Medicine, Tokyo, Japan." } }, { "@type": "Person", "name": "Nir Sorkin", "url": "https://questionsmedicales.fr/author/Nir%20Sorkin", "affiliation": { "@type": "Organization", "name": "Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada." } }, { "@type": "Person", "name": "Clara C Chan", "url": "https://questionsmedicales.fr/author/Clara%20C%20Chan", "affiliation": { "@type": "Organization", "name": "Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada." } }, { "@type": "Person", "name": "David S Rootman", "url": "https://questionsmedicales.fr/author/David%20S%20Rootman", "affiliation": { "@type": "Organization", "name": "Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.", "datePublished": "2024-04-29", "url": "https://questionsmedicales.fr/article/38756630", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.21037/jgo-24-218" } }, { "@type": "ScholarlyArticle", "name": "Intensity-modulated proton and carbon-ion radiotherapy using fixed-beam system for locally advanced lung cancer: dosimetric comparison with x-ray radiotherapy and normal tissue complication probability (NTCP) evaluation.", "datePublished": "2023-12-08", "url": "https://questionsmedicales.fr/article/38064747", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1088/1361-6560/ad13d1" } }, { "@type": "ScholarlyArticle", "name": "A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.", "datePublished": "2023-06-02", "url": "https://questionsmedicales.fr/article/37271306", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.diabet.2023.101455" } }, { "@type": "ScholarlyArticle", "name": "Proteomic profiling reveals KRT6C as a probable hereterodimer partner for KRT9: New insights into re-classifying epidermolytic palmoplantar keratoderma (EPPK) and a milder form of pachyonychia congenita (PC-K6c) as a group of genetic cutaneous disorders.", "datePublished": "2023-07-17", "url": "https://questionsmedicales.fr/article/37467889", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jprot.2023.104971" } }, { "@type": "ScholarlyArticle", "name": "Cluster-Based Toxicity Estimation of Osteoradionecrosis via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification.", "datePublished": "2024-03-08", "url": "https://questionsmedicales.fr/article/38462018", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ijrobp.2024.02.021" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Tissus", "item": "https://questionsmedicales.fr/mesh/D014024" }, { "@type": "ListItem", "position": 3, "name": "Membranes", "item": "https://questionsmedicales.fr/mesh/D008566" }, { "@type": "ListItem", "position": 4, "name": "Membrane basale", "item": "https://questionsmedicales.fr/mesh/D001485" }, { "@type": "ListItem", "position": 5, "name": "Lame limitante postérieure", "item": "https://questionsmedicales.fr/mesh/D003886" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Lame limitante postérieure - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Lame limitante postérieure", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Lame limitante postérieure", "description": "Comment diagnostiquer une pathologie de la membrane de Descemet ?\nQuels tests sont utilisés pour évaluer la membrane de Descemet ?\nQuels signes indiquent une défaillance de la membrane de Descemet ?\nLa biopsie est-elle nécessaire pour diagnostiquer des anomalies ?\nQuels symptômes peuvent indiquer un problème avec la membrane de Descemet ?", "url": "https://questionsmedicales.fr/mesh/D003886?mesh_terms=Probability&page=272#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Lame limitante postérieure", "description": "Quels sont les symptômes d'une défaillance de la membrane de Descemet ?\nLa rougeur de l'œil est-elle un symptôme associé ?\nPeut-on ressentir des démangeaisons avec des problèmes de Descemet ?\nLes troubles visuels sont-ils fréquents avec des anomalies de Descemet ?\nLa douleur oculaire est-elle un symptôme courant ?", "url": "https://questionsmedicales.fr/mesh/D003886?mesh_terms=Probability&page=272#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Lame limitante postérieure", "description": "Comment prévenir les problèmes de la membrane de Descemet ?\nLes examens réguliers des yeux sont-ils importants ?\nUne bonne hygiène oculaire peut-elle prévenir des problèmes ?\nLes allergies oculaires peuvent-elles affecter la membrane de Descemet ?\nLe port de lentilles de contact nécessite-t-il des précautions ?", "url": "https://questionsmedicales.fr/mesh/D003886?mesh_terms=Probability&page=272#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Lame limitante postérieure", "description": "Quels traitements sont disponibles pour les problèmes de Descemet ?\nLa greffe de cornée est-elle une option de traitement ?\nLes gouttes oculaires peuvent-elles aider ?\nY a-t-il des traitements non chirurgicaux disponibles ?\nLes traitements varient-ils selon la gravité de la condition ?", "url": "https://questionsmedicales.fr/mesh/D003886?mesh_terms=Probability&page=272#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Lame limitante postérieure", "description": "Quelles complications peuvent survenir avec des problèmes de Descemet ?\nL'infection est-elle une complication possible ?\nLes cicatrices cornéennes peuvent-elles résulter de problèmes de Descemet ?\nPeut-on développer un glaucome à cause de problèmes de Descemet ?\nLes complications peuvent-elles nécessiter une intervention chirurgicale ?", "url": "https://questionsmedicales.fr/mesh/D003886?mesh_terms=Probability&page=272#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Lame limitante postérieure", "description": "Quels sont les facteurs de risque pour les problèmes de Descemet ?\nL'âge est-il un facteur de risque ?\nLes maladies systémiques influencent-elles la santé de Descemet ?\nLe port de lentilles de contact est-il un facteur de risque ?\nLes allergies peuvent-elles être un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D003886?mesh_terms=Probability&page=272#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une pathologie de la membrane de Descemet ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un examen ophtalmologique complet, incluant la tomographie et la microscopie, est essentiel." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer la membrane de Descemet ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "La pachymétrie et l'optique cohérente par tomographie sont couramment utilisés." } }, { "@type": "Question", "name": "Quels signes indiquent une défaillance de la membrane de Descemet ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Un œdème cornéen et une opacité cornéenne peuvent signaler une défaillance." } }, { "@type": "Question", "name": "La biopsie est-elle nécessaire pour diagnostiquer des anomalies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "La biopsie n'est généralement pas nécessaire, les examens non invasifs suffisent." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec la membrane de Descemet ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Vision floue, douleur oculaire et rougeur peuvent indiquer un problème." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une défaillance de la membrane de Descemet ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent vision floue, douleur, et sensibilité à la lumière." } }, { "@type": "Question", "name": "La rougeur de l'œil est-elle un symptôme associé ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la rougeur de l'œil peut être un symptôme d'inflammation ou d'irritation." } }, { "@type": "Question", "name": "Peut-on ressentir des démangeaisons avec des problèmes de Descemet ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des démangeaisons peuvent survenir en raison d'irritation ou d'allergies." } }, { "@type": "Question", "name": "Les troubles visuels sont-ils fréquents avec des anomalies de Descemet ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les troubles visuels sont fréquents et peuvent varier en gravité." } }, { "@type": "Question", "name": "La douleur oculaire est-elle un symptôme courant ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la douleur oculaire est un symptôme courant associé aux problèmes de Descemet." } }, { "@type": "Question", "name": "Comment prévenir les problèmes de la membrane de Descemet ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les traumatismes oculaires et porter des lunettes de protection peut aider." } }, { "@type": "Question", "name": "Les examens réguliers des yeux sont-ils importants ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des examens réguliers permettent de détecter précocement les problèmes." } }, { "@type": "Question", "name": "Une bonne hygiène oculaire peut-elle prévenir des problèmes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, maintenir une bonne hygiène oculaire aide à prévenir les infections et irritations." } }, { "@type": "Question", "name": "Les allergies oculaires peuvent-elles affecter la membrane de Descemet ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les allergies peuvent provoquer des inflammations affectant la membrane." } }, { "@type": "Question", "name": "Le port de lentilles de contact nécessite-t-il des précautions ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est crucial de suivre les recommandations pour éviter les complications." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les problèmes de Descemet ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des médicaments anti-inflammatoires et des interventions chirurgicales." } }, { "@type": "Question", "name": "La greffe de cornée est-elle une option de traitement ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la greffe de cornée peut être nécessaire en cas de défaillance sévère." } }, { "@type": "Question", "name": "Les gouttes oculaires peuvent-elles aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des gouttes oculaires peuvent réduire l'inflammation et améliorer le confort." } }, { "@type": "Question", "name": "Y a-t-il des traitements non chirurgicaux disponibles ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements médicaux et des thérapies de soutien sont disponibles." } }, { "@type": "Question", "name": "Les traitements varient-ils selon la gravité de la condition ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont adaptés en fonction de la gravité et des symptômes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des problèmes de Descemet ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'œdème cornéen, la perte de vision et l'infection." } }, { "@type": "Question", "name": "L'infection est-elle une complication possible ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une infection peut survenir, surtout après une chirurgie ou un traumatisme." } }, { "@type": "Question", "name": "Les cicatrices cornéennes peuvent-elles résulter de problèmes de Descemet ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des cicatrices peuvent se former, affectant la clarté de la vision." } }, { "@type": "Question", "name": "Peut-on développer un glaucome à cause de problèmes de Descemet ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des problèmes de Descemet peuvent augmenter le risque de glaucome." } }, { "@type": "Question", "name": "Les complications peuvent-elles nécessiter une intervention chirurgicale ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines complications graves peuvent nécessiter une intervention chirurgicale." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les problèmes de Descemet ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux, les traumatismes oculaires et certaines maladies augmentent le risque." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut augmenter le risque de défaillance de la membrane de Descemet." } }, { "@type": "Question", "name": "Les maladies systémiques influencent-elles la santé de Descemet ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme le diabète peuvent affecter la santé cornéenne." } }, { "@type": "Question", "name": "Le port de lentilles de contact est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un usage inapproprié des lentilles peut augmenter le risque d'infections." } }, { "@type": "Question", "name": "Les allergies peuvent-elles être un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les allergies oculaires peuvent contribuer à l'inflammation et aux problèmes de Descemet." } } ] } ] }

Sources (2727 au total)

Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.

While surufatinib, sunitinib, and everolimus have shown efficacy for advanced neuroendocrine neoplasms (NENs) in randomized controlled trials (RCTs), direct comparisons in a real-world setting remain ... A retrospective, observational study was conducted at Fudan University Shanghai Cancer Center, including patients with advanced NENs treated with surufatinib, sunitinib, or everolimus between July 202... The study enrolled 123, 56, and 68 locally advanced or metastatic NEN patients treated with surufatinib, sunitinib, and everolimus, respectively. Before adjusting for confounding factors, surufatinib ... In a real-world Chinese cohort, surufatinib significantly outperformed sunitinib and everolimus in prolonging PFS among advanced NEN patients, with identifiable clinical features impacting survival, a...

A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.

The classical glycosylated hemoglobin A1c threshold of 6.5% is an insensitive screening test for cystic fibrosis-related diabetes (CFRD). We sought to identify CF-specific A1C thresholds associated wi... We studied the cross sectional and longitudinal associations between A1c, BMI, and FEV1 in 2 cohorts of 223 children (followed for up to 8 years) and 289 adults (followed for a mean of 7.5 ± 4.3 years... For the onset of OGTT-defined CFRD optimal A1c threshold was 5.9% in adults (sensitivity: 67% and specificity: 71%) and 5.7% for children (sensitivity: 60% and specificity: 47%). Kaplan-Meier analysis... An A1C above 6% may be associated with a high risk of developing CFRD and a lower probability of weight gain in both adults and children with CF....

Proteomic profiling reveals KRT6C as a probable hereterodimer partner for KRT9: New insights into re-classifying epidermolytic palmoplantar keratoderma (EPPK) and a milder form of pachyonychia congenita (PC-K6c) as a group of genetic cutaneous disorders.

Epidermolytic palmoplantar keratoderma (EPPK), a highly penetrant autosomal dominant genodermatosis, is characterized by diffuse keratoses on palmplantar epidermis. The keratin 9 gene (KRT9) is respon...

Cluster-Based Toxicity Estimation of Osteoradionecrosis via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification.

Given the limitations of extant models for normal tissue complication probability estimation for osteoradionecrosis (ORN) of the mandible, the purpose of this study was to enrich statistical inference... The analysis was conducted on retrospective data of 1,259 head and neck cancer (HNC) patients treated at XXX between 2005 and 2015. During a minimum 12-month post-therapy follow-up period, 173 patient... The K-means clustering method identified six clusters among the DVHs. Based on the first five clusters, the dose-volume space was partitioned by the soft-margin SVM into distinct regions with differen... This study presents an unsupervised-learning analysis of a large-scale data set to evaluate the risk of mandibular ORN among HNC patients. The results provide a visual risk-assessment tool for ORN (ba...

Long-term oral administration of Huaier granules improves survival outcomes in hepatocellular carcinoma patients within Milan criteria following microwave ablation: a propensity score matching and stabilized inverse probability weighting analysis.

This study aimed to elucidate the therapeutic effects of Huaier granules on hepatocellular carcinoma (HCC) within the Milan criteria in patients who underwent microwave ablation (MWA).... A total of 228 patients were included, with 97 in the Huaier group and 131 in the control group. We evaluated progression-free survival (PFS), overall survival (OS), and extrahepatic metastasis surviv... Following PSM, the 1-, 3-, and 5-year PFS rates in the Huaier and control groups were 83.5% vs 70.7%, 57.7% vs 42.6%, and 43.6% vs 31.9% (... Huaier granules can reduce the risk of recurrence and improve the OS of patients with HCC within the Milan criteria following MWA. Administering Huaier granules for over 6 months proved beneficial....

Cluster-Based Toxicity Estimation of Osteoradionecrosis via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification.

Given the limitations of extant models for normal tissue complication probability estimation for osteoradionecrosis (ORN) of the mandible, the purpose of this study was to enrich statistical inference... The analysis was conducted on retrospective data of 1,259 head and neck cancer (HNC) patients treated at the University of Texas MD Anderson Cancer Center between 2005 and 2015. The (structural) clust... The K-means clustering method identified six clusters among the DVHs. Based on the first five clusters, the dose-volume space was partitioned almost perfectly by the soft-margin SVM into distinct regi... This study presents an unsupervised-learning analysis of a large-scale data set to evaluate the risk of mandibular ORN among HNC patients. The results provide a visual risk-assessment tool (based on t...

Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT).

The cardiovascular and renal outcomes of angiotensin-II receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) treatment are well-known; however, few studies have evaluated initiati... To emulate a target trial to evaluate the cognitive outcomes of initiating an ARB- vs ACEI-based antihypertensive regimen in individuals at risk for mild cognitive impairment (MCI) and probable dement... Active comparator, new-user observational cohort study design using data from the Systolic Blood Pressure Intervention Trial (SPRINT), conducted November 2010 through July 2018. Marginal cause-specifi... New users of ARB vs ACEI during the first 12 months of trial follow-up.... Composite of adjudicated amnestic MCI or PD.... Of 9361 participants, 727 and 1313 new users of an ARB or ACEI, respectively, with well-balanced baseline characteristics between medication exposure groups after inverse probability weighting (mean [... In this observational cohort study of US adults at high cardiovascular disease risk, there was no difference in the rate of amnestic MCI or PD among new users of an ARB compared with ACEI, although 95...

Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.

To assess the relationship between renal function and efficacy/safety of imipenem/cilastatin/relebactam for the treatment of hospital-acquired/ventilator-associated pneumonia (HABP/VABP) from RESTORE-... Adults with HABP/VABP were randomized 1:1 to IV imipenem/cilastatin/relebactam 1.25 g or piperacillin/tazobactam 4.5 g every 6 h for 7-14 days. Initial doses were selected by CL... The modified ITT population comprised those with normal renal function (... Prescribing information-defined dose adjustments in participants with baseline RI and full dosing of imipenem/cilastatin/relebactam 1.25 g every 6 h for participants with normal renal function or augm...